Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: EBF2

Gene summary for EBF2

Gene summary.

Gene information	Species	Human
	Gene symbol	EBF2
	Gene ID	64641
	Gene name	EBF transcription factor 2
	Gene Alias	COE2
	Cytomap	8p21.2
	Gene Type	protein-coding
	GO ID	GO:0001659
	UniProtAcc	B2RNT0

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
64641	EBF2	ATC12	Human	Thyroid	ATC	4.23e-28	5.17e-01	0.34
64641	EBF2	ATC13	Human	Thyroid	ATC	1.88e-57	9.99e-01	0.34
64641	EBF2	ATC4	Human	Thyroid	ATC	2.45e-37	6.47e-01	0.34
64641	EBF2	ATC5	Human	Thyroid	ATC	1.85e-55	1.08e+00	0.34

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000042219	Skin	cSCC	autophagy of mitochondrion	44/4864	81/18723	5.28e-08	1.36e-06	44
GO:006172619	Skin	cSCC	mitochondrion disassembly	44/4864	81/18723	5.28e-08	1.36e-06	44
GO:0010821111	Skin	cSCC	regulation of mitochondrion organization	67/4864	144/18723	7.99e-08	1.96e-06	67
GO:000698423	Skin	cSCC	ER-nucleus signaling pathway	29/4864	46/18723	1.33e-07	3.05e-06	29
GO:007149628	Skin	cSCC	cellular response to external stimulus	125/4864	320/18723	1.63e-07	3.65e-06	125
GO:19035339	Skin	cSCC	regulation of protein targeting	39/4864	81/18723	1.46e-05	1.81e-04	39
GO:003166825	Skin	cSCC	cellular response to extracellular stimulus	94/4864	246/18723	1.52e-05	1.87e-04	94
GO:190374716	Skin	cSCC	regulation of establishment of protein localization to mitochondrion	27/4864	50/18723	2.26e-05	2.62e-04	27
GO:000926722	Skin	cSCC	cellular response to starvation	64/4864	156/18723	2.79e-05	3.12e-04	64
GO:0042594110	Skin	cSCC	response to starvation	77/4864	197/18723	3.52e-05	3.82e-04	77
GO:19032149	Skin	cSCC	regulation of protein targeting to mitochondrion	24/4864	44/18723	5.16e-05	5.28e-04	24
GO:003166728	Skin	cSCC	response to nutrient levels	160/4864	474/18723	8.44e-05	8.02e-04	160
GO:003166925	Skin	cSCC	cellular response to nutrient levels	80/4864	215/18723	1.76e-04	1.50e-03	80
GO:190374915	Skin	cSCC	positive regulation of establishment of protein localization to mitochondrion	19/4864	36/18723	5.40e-04	4.00e-03	19
GO:19039557	Skin	cSCC	positive regulation of protein targeting to mitochondrion	17/4864	32/18723	9.55e-04	6.47e-03	17
GO:190314615	Skin	cSCC	regulation of autophagy of mitochondrion	17/4864	33/18723	1.50e-03	9.36e-03	17
GO:19026525	Skin	cSCC	secondary alcohol metabolic process	53/4864	147/18723	4.33e-03	2.27e-02	53
GO:005123527	Skin	cSCC	maintenance of location	106/4864	327/18723	5.17e-03	2.61e-02	106
GO:003293313	Skin	cSCC	SREBP signaling pathway	9/4864	15/18723	5.52e-03	2.73e-02	9
GO:000721922	Skin	cSCC	Notch signaling pathway	60/4864	172/18723	5.82e-03	2.87e-02	60

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

TF	Cell Type	Tissue	Disease Stage	Target Gene	RSS	Regulon Activity
EBF2	ECM	Oral cavity	ADJ	PLAC9,EFHD1,MFAP5, etc.	7.18e-01
EBF2	ECM	Oral cavity	OSCC	PLAC9,EFHD1,MFAP5, etc.	1.13e-01

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

EBF2

SNV

Missense_Mutation

c.1373C>T

p.Pro458Leu

p.P458L

Q9HAK2

protein_coding

deleterious_low_confidence(0.04)

possibly_damaging(0.593)

TCGA-A7-A26H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

anastrozole

EBF2

SNV

Missense_Mutation

novel

c.202N>T

p.His68Tyr

p.H68Y

Q9HAK2

protein_coding

deleterious(0)

probably_damaging(0.911)

TCGA-AC-A2QI-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

cytoxan

EBF2

SNV

Missense_Mutation

c.469N>A

p.Glu157Lys

p.E157K

Q9HAK2

protein_coding

deleterious(0)

possibly_damaging(0.6)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

EBF2

SNV

Missense_Mutation

c.1468N>G

p.Leu490Val

p.L490V

Q9HAK2

protein_coding

deleterious_low_confidence(0.02)

possibly_damaging(0.816)

TCGA-BH-A0AW-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

carboplatin

EBF2

SNV

Missense_Mutation

c.421N>A

p.Glu141Lys

p.E141K

Q9HAK2

protein_coding

deleterious(0.02)

probably_damaging(0.997)

TCGA-BH-A0DP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

arimidex

EBF2

SNV

Missense_Mutation

novel

c.1204N>G

p.Leu402Val

p.L402V

Q9HAK2

protein_coding

deleterious_low_confidence(0.03)

probably_damaging(0.911)

TCGA-BH-A2L8-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

EBF2

SNV

Missense_Mutation

novel

c.599C>G

p.Thr200Arg

p.T200R

Q9HAK2

protein_coding

deleterious(0)

benign(0.142)

TCGA-D8-A1JP-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

EBF2

SNV

Missense_Mutation

novel

c.725N>C

p.Arg242Thr

p.R242T

Q9HAK2

protein_coding

deleterious(0)

possibly_damaging(0.491)

TCGA-EW-A423-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

anastrozole

EBF2

SNV

Missense_Mutation

novel

c.8N>A

p.Gly3Glu

p.G3E

Q9HAK2

protein_coding

deleterious_low_confidence(0.04)

benign(0.018)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

EBF2

SNV

Missense_Mutation

c.1138C>G

p.Leu380Val

p.L380V

Q9HAK2

protein_coding

tolerated(0.06)

benign(0.148)

TCGA-VS-A954-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1